Go offline with the Player FM app!
Making Sense of the Expanding Options in Metastatic Colorectal Cancer Care: Part 1
Manage episode 323360242 series 3264057
In this first of two podcasts, oncologists discuss the latest evidence that informs how they select first-line treatment regimens for patients with metastatic colorectal cancer. Using cases for a patient-centered approach, they explore the recommended testing for mutations and biomarkers that impact metastatic colorectal cancer, how to plan strategies for incorporating novel agents into the treatment of patients and recommended strategies to identify and manage toxicities of novel agents for metastatic colorectal cancer. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.
Contributors:
Joleen Hubbard MD
Cathy Eng, MD
Stephanie Andrews, MS, APRN-C
Ms Andrews: fees for non-CME/CE services: Genentech.
Dr Eng: consulting fees: Amgen, GlaxoSmithKline, Hoopika, Natera; contracted research (paid to institution): Merck, Pfizer.
Dr Hubbard: advisor: BeiGene; advisor/researcher: Bayer, Boston Biomedical, G1 Therapeutics, Hutchison MediPharma, Incyte, Merck, Pionyr Immunotherapeutics, Seagen, Senhwa Pharmaceuticals, Roche, Treos Bio, TriOncology, Trovogene.
90 episodes
Manage episode 323360242 series 3264057
In this first of two podcasts, oncologists discuss the latest evidence that informs how they select first-line treatment regimens for patients with metastatic colorectal cancer. Using cases for a patient-centered approach, they explore the recommended testing for mutations and biomarkers that impact metastatic colorectal cancer, how to plan strategies for incorporating novel agents into the treatment of patients and recommended strategies to identify and manage toxicities of novel agents for metastatic colorectal cancer. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.
Contributors:
Joleen Hubbard MD
Cathy Eng, MD
Stephanie Andrews, MS, APRN-C
Ms Andrews: fees for non-CME/CE services: Genentech.
Dr Eng: consulting fees: Amgen, GlaxoSmithKline, Hoopika, Natera; contracted research (paid to institution): Merck, Pfizer.
Dr Hubbard: advisor: BeiGene; advisor/researcher: Bayer, Boston Biomedical, G1 Therapeutics, Hutchison MediPharma, Incyte, Merck, Pionyr Immunotherapeutics, Seagen, Senhwa Pharmaceuticals, Roche, Treos Bio, TriOncology, Trovogene.
90 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.